TuHURA Biosciences (HURA) Notes Payables (2017 - 2025)

TuHURA Biosciences' (HURA) quarterly Notes Payables came in at $493386.0 in Q3 2025, up 13.68% quarter-over-quarter from $434000.0 in Q2 2025.

TuHURA Biosciences (HURA) Notes Payables (2017 - 2025) Analysis & Trends

TuHURA Biosciences' Notes Payables history runs 4 years deep, the most recent figure standing at $493386.0 for Q3 2025.

On a quarterly basis, Notes Payables changed N/A year-over-year to $493386.0 in Q3 2025; TTM through Sep 2025 was $493386.0, a N/A change from a year earlier, with the FY2023 full-year figure at $137000.0, changed N/A from the prior year.
Notes Payables advanced to $493386.0 in Q3 2025 per HURA's latest filing, from $434000.0 in the prior quarter.
Across five years, Notes Payables topped out at $493386.0 in Q3 2025 and bottomed at $137000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	TuHURA Biosciences	132.62 Mn	132.62 Mn	-

Download Data